MA56883B1 - Dérivés de 2-hydroxycycloalcane-1-carbamoyle - Google Patents
Dérivés de 2-hydroxycycloalcane-1-carbamoyleInfo
- Publication number
- MA56883B1 MA56883B1 MA56883A MA56883A MA56883B1 MA 56883 B1 MA56883 B1 MA 56883B1 MA 56883 A MA56883 A MA 56883A MA 56883 A MA56883 A MA 56883A MA 56883 B1 MA56883 B1 MA 56883B1
- Authority
- MA
- Morocco
- Prior art keywords
- hydroxycycloalkane
- carbamoyl derivatives
- compounds
- formula
- carbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019071921 | 2019-08-15 | ||
| PCT/EP2020/072865 WO2021028570A1 (en) | 2019-08-15 | 2020-08-14 | 2-hydroxycycloalkane-1-carbamoyl derivatives |
| EP20767476.3A EP4013751B1 (en) | 2019-08-15 | 2020-08-14 | 2-hydroxycycloalkane-1-carbamoyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56883B1 true MA56883B1 (fr) | 2025-04-30 |
Family
ID=72355943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56883A MA56883B1 (fr) | 2019-08-15 | 2020-08-14 | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12291519B2 (https=) |
| EP (1) | EP4013751B1 (https=) |
| JP (1) | JP7604457B2 (https=) |
| KR (1) | KR102832308B1 (https=) |
| CN (1) | CN114269737A (https=) |
| AU (1) | AU2020329609B2 (https=) |
| BR (1) | BR112021026829A2 (https=) |
| CA (1) | CA3147454A1 (https=) |
| ES (1) | ES3015725T3 (https=) |
| HR (1) | HRP20250372T1 (https=) |
| HU (1) | HUE070924T2 (https=) |
| IL (1) | IL289197B2 (https=) |
| MA (1) | MA56883B1 (https=) |
| MX (1) | MX2022001789A (https=) |
| PH (1) | PH12022550338A1 (https=) |
| PL (1) | PL4013751T3 (https=) |
| RS (1) | RS66695B1 (https=) |
| TW (1) | TWI864071B (https=) |
| UA (1) | UA128909C2 (https=) |
| WO (1) | WO2021028570A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| EP4010348B1 (en) | 2019-08-09 | 2023-12-20 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| CA3148365A1 (en) | 2019-08-29 | 2021-03-04 | Martin Bolli | Alpha-d-galactopyranoside derivatives |
| CA3161794A1 (en) * | 2019-12-24 | 2021-07-01 | John L. Magnani | Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols |
| ES3014851T3 (en) | 2020-10-06 | 2025-04-25 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| KR20230104190A (ko) | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| KR20230145111A (ko) * | 2021-02-09 | 2023-10-17 | 이도르시아 파마슈티컬스 리미티드 | 히드록시헤테로시클로알칸-카르바모일 유도체 |
| PL4301748T3 (pl) | 2021-03-03 | 2025-09-08 | Idorsia Pharmaceuticals Ltd | Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu |
| WO2022189459A2 (en) * | 2021-03-10 | 2022-09-15 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| JP2024517936A (ja) * | 2021-05-14 | 2024-04-23 | グリコミメティクス， インコーポレイテッド | ガレクチン－３阻害性ｃ－グリコシド |
| WO2022250976A1 (en) * | 2021-05-28 | 2022-12-01 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycoside oximes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| WO2014078655A1 (en) | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| JP6904906B2 (ja) * | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| KR101974793B1 (ko) | 2015-07-06 | 2019-05-02 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| CA3025867A1 (en) | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CA3062648A1 (en) * | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US20200061095A1 (en) * | 2017-05-12 | 2020-02-27 | Galectin Sciences, Llc | Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof |
| WO2019067702A1 (en) * | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| AU2018361991A1 (en) | 2017-10-31 | 2020-05-14 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| CN113366007A (zh) | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| JP2022508719A (ja) | 2018-10-15 | 2022-01-19 | ガレクト バイオテック エービー | ガレクチンのガラクトシド阻害剤のプロドラッグ |
| JP7486484B2 (ja) | 2018-11-21 | 2024-05-17 | ガレクト バイオテック エービー | ガレクチンのα－Ｄ－ガラクトシド阻害剤 |
| EP3953349A1 (en) | 2019-04-10 | 2022-02-16 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| CA3141436A1 (en) | 2019-07-03 | 2021-01-07 | Fredrik Zetterberg | Novel galactoside inhibitor of galectins |
| CN114450282A (zh) | 2019-07-05 | 2022-05-06 | 格莱克特生物技术公司 | 半乳糖凝集素的新型半乳糖苷抑制剂 |
| EP4010348B1 (en) | 2019-08-09 | 2023-12-20 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| CA3148365A1 (en) | 2019-08-29 | 2021-03-04 | Martin Bolli | Alpha-d-galactopyranoside derivatives |
| ES3014851T3 (en) | 2020-10-06 | 2025-04-25 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| KR20230104190A (ko) | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| KR20230145111A (ko) | 2021-02-09 | 2023-10-17 | 이도르시아 파마슈티컬스 리미티드 | 히드록시헤테로시클로알칸-카르바모일 유도체 |
| PL4301748T3 (pl) | 2021-03-03 | 2025-09-08 | Idorsia Pharmaceuticals Ltd | Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu |
-
2020
- 2020-08-14 JP JP2022508567A patent/JP7604457B2/ja active Active
- 2020-08-14 WO PCT/EP2020/072865 patent/WO2021028570A1/en not_active Ceased
- 2020-08-14 EP EP20767476.3A patent/EP4013751B1/en active Active
- 2020-08-14 HU HUE20767476A patent/HUE070924T2/hu unknown
- 2020-08-14 ES ES20767476T patent/ES3015725T3/es active Active
- 2020-08-14 MA MA56883A patent/MA56883B1/fr unknown
- 2020-08-14 KR KR1020227006817A patent/KR102832308B1/ko active Active
- 2020-08-14 UA UAA202200939A patent/UA128909C2/uk unknown
- 2020-08-14 IL IL289197A patent/IL289197B2/en unknown
- 2020-08-14 HR HRP20250372TT patent/HRP20250372T1/hr unknown
- 2020-08-14 AU AU2020329609A patent/AU2020329609B2/en active Active
- 2020-08-14 US US17/634,512 patent/US12291519B2/en active Active
- 2020-08-14 PH PH1/2022/550338A patent/PH12022550338A1/en unknown
- 2020-08-14 BR BR112021026829A patent/BR112021026829A2/pt unknown
- 2020-08-14 CN CN202080057325.7A patent/CN114269737A/zh active Pending
- 2020-08-14 TW TW109127800A patent/TWI864071B/zh active
- 2020-08-14 RS RS20250349A patent/RS66695B1/sr unknown
- 2020-08-14 MX MX2022001789A patent/MX2022001789A/es unknown
- 2020-08-14 PL PL20767476.3T patent/PL4013751T3/pl unknown
- 2020-08-14 CA CA3147454A patent/CA3147454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL289197A (en) | 2022-02-01 |
| IL289197B2 (en) | 2026-02-01 |
| CA3147454A1 (en) | 2021-02-18 |
| RS66695B1 (sr) | 2025-05-30 |
| JP2022544248A (ja) | 2022-10-17 |
| IL289197B1 (en) | 2025-10-01 |
| JP7604457B2 (ja) | 2024-12-23 |
| ES3015725T3 (en) | 2025-05-07 |
| PL4013751T3 (pl) | 2025-05-19 |
| AU2020329609A1 (en) | 2022-02-24 |
| EP4013751B1 (en) | 2025-01-22 |
| WO2021028570A1 (en) | 2021-02-18 |
| HRP20250372T1 (hr) | 2025-06-06 |
| UA128909C2 (uk) | 2024-11-20 |
| EP4013751A1 (en) | 2022-06-22 |
| US12291519B2 (en) | 2025-05-06 |
| MX2022001789A (es) | 2022-03-11 |
| BR112021026829A2 (pt) | 2022-02-22 |
| AU2020329609B2 (en) | 2025-10-02 |
| PH12022550338A1 (en) | 2023-02-06 |
| KR102832308B1 (ko) | 2025-07-10 |
| TW202115039A (zh) | 2021-04-16 |
| US20220324847A1 (en) | 2022-10-13 |
| TWI864071B (zh) | 2024-12-01 |
| CN114269737A (zh) | 2022-04-01 |
| KR20220047585A (ko) | 2022-04-18 |
| HUE070924T2 (hu) | 2025-07-28 |
| EP4013751C0 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA55046B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA29926B1 (fr) | Derives de pyrazine | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA45223A (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA31754B1 (fr) | Cis-imidazolines chirales | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA63589B1 (fr) | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
| MA30487B1 (fr) | Nouveaux composes heterocycliques | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| CA3156303A1 (en) | 5-fluoronicotinamide derivatives and uses thereof |